Table 3 Outcomes with IC/HMA + TKI based on TKI generation
From: Impact of frontline treatment approach on outcomes of myeloid blast phase CML
| Outcome | N (%) | ||
|---|---|---|---|
|
IC/HMA + imatinib (N = 7) |
IC/HMA + 2nd generation TKI (N = 25) |
IC/HMA + ponatinib (N = 8) | |
| CR | 1 (14.3%) | 11 (44%) | 3 (37.5%) |
| CR/CRi | 2 (28.6%) | 16 (64%) | 5 (62.5%) |
| CR/CRi/MLFS | 4 (57.1%) | 19 (76%) | 7 (87.5%) |
| 5-year CIR | 100% | 45% | 38% |
| 5-year EFS | 0% | 25% | 38% |
| 5-year OS | 0% | 32% | 38% |